Richard Kender
Director/Board Member at POXEL
Net worth: 466 218 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Pierre Legault | M | 63 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 years |
Eric Shaff | M | 48 | 10 years | |
Janice Bourque | F | 67 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 years |
Kevin Lee | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK. | 9 years |
Veronica Jordan | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 years |
Marcus Chapman | M | 53 | 9 years | |
Sebastien Bolze | M | - | 15 years | |
Kevin Finney | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 5 years |
Stephen Berenson | M | 63 | 5 years | |
Mohammed Khoso Baluch | M | 66 | 12 years | |
Thomas Kuhn | M | 50 | 15 years | |
Michael Skynner | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 years |
Kate Bingham | F | 58 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK. | 8 years |
Pascale Fouqueray-Grellier | M | 61 | 15 years | |
Alistair Milnes | M | 50 | 3 years | |
Gregory Winter | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The private company is based in Babraham, UK. | 15 years |
Matthew Henn | M | 49 | 12 years | |
Willard Dere | M | 70 | 7 years | |
Tom Glocer | M | 63 | 17 years | |
Carlo Tanzi | M | - | 9 years | |
Nancy Thornberry | F | 67 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 20 years |
Chirfi Guindo | M | 58 | 13 years | |
Jennifer Russo Wortman | F | - | 9 years | |
David Ege | M | 50 | 21 years | |
Dalton Smart | M | 58 | 15 years | |
Stephen Sands | M | 67 | - | |
Gary O'Neill | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 11 years |
Paul Schimmel | M | 83 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 13 years |
Kurt Graves | M | 56 | 9 years | |
Patricia Russo | F | 71 | 29 years | |
Peter Wendell | M | 73 | 21 years | |
Dennis Ausiello | M | 78 | 9 years | |
Thomas DesRosier | M | 69 | 8 years | |
Jose-Carlos Gutiérrez-Ramos | M | 61 | 3 years | |
Claire Fraser-Liggett | M | 68 | 1 years | |
Travis Thompson | M | - | 6 years | |
Paul Biondi | M | 54 | 4 years | |
Caroline Litchfield | F | 55 | 34 years | |
Pascale Boissel | F | 57 | 9 years | |
Sophie Hallakou-Bozec | M | - | 15 years | |
Richard DeLuca | M | 61 | 13 years | |
James Sutcliffe | M | 68 | 1 years | |
Steven Graziano | M | - | 18 years | |
Gregory Fu | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | - |
Sylvie Bertrand | F | - | 3 years | |
Naveed Iqbal Siddiqi | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 3 years |
Kate Bingham | F | - |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | - |
Sanat Chattopadhyay | M | - | 15 years | |
Quentin Durand | M | - | 5 years | |
James Matteucci | M | - | 21 years | |
Chan Beals | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 8 years |
Barbara McGovern | M | - | 9 years | |
Denise Williams | F | - | 15 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert P. Luciano | M | - | 23 years | |
Richard Kogan | M | 81 | 21 years | |
Kenneth Frazier | M | 69 | 30 years | |
P. Vagelos | M | 94 | 19 years | |
Roger Pomerantz | M | 67 | 9 years | |
Raymond Gilmartin | M | 82 | 2 years | |
John G. Aunins | M | 63 | 31 years | |
David Berry | M | 47 | 5 years | |
Lee Kalowski | M | 43 | 6 years | |
Richard Clark | M | 77 | 6 years | |
Myrtle Potter | F | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support.
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | 18 years |
Noubar Afeyan | M | 60 | 10 years | |
Fred Hassan | M | 78 | 6 years | |
James Corbett | M | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 4 years |
Robert Palmisano | M | 79 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 2 years |
David Arkowitz | M | 62 | 7 years | |
David Norton | M | 72 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 2 years |
Kevin J. Horgan | M | 64 | 8 years | |
Deborah Harland | M | 64 | 10 years | |
Ismail Kola | M | 67 | 4 years | |
Meryl Zausner | F | 67 | 5 years | |
Thomas C. Südhof | M | 68 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 1 years |
William Harrison | M | 80 | - | |
Caroline Dorsa | F | 64 | 22 years | |
David N. Cook | M | 66 | 7 years | |
Lorence Kim | M | 49 | 6 years | |
Grégory Behar | M | 55 | 9 years | |
Robert Iannone | M | 57 | 6 years | |
Kumi Sato | F | - | 6 years | |
Laura Sepp-Lorenzino | M | 63 | 15 years | |
Richard Henriques | M | 68 | 27 years | |
David Burgstahler | M | 55 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 7 years |
Linda Harty | F | 63 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Anne Tatlock | F | 84 | - | |
Charles Harwood | M | 70 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 6 years |
Peter Wilkinson | M | 53 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 3 years |
William Klitgaard | M | 71 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
James Bannon | M | 71 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 4 years |
Richard Markham | M | 73 | 20 years | |
Rochelle Lazarus | F | 76 | 16 years | |
Duncan MacDonald | M | 56 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 6 years |
Ken Meyers | M | 62 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Charles Kidder | M | 79 | 12 years | |
Steven Goldstone | M | 78 | 6 years | |
Wendell Weeks | M | 64 | 16 years | |
William N. Kelley | M | 84 | - | |
Natarajan Sethuraman | M | 62 | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 81 | 81.00% |
United Kingdom | 15 | 15.00% |
France | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Kender
- Personal Network